Edoxaban API Market, Global Outlook and Forecast 2024-2031

Report ID: 1067224 | Published Date: Jan 2025 | No. of Page: 73 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story

Edoxaban is an oral anticoagulant drug which acts as a direct factor Xa inhibitor.
This report contains market size and forecasts of Edoxaban API in global, including the following market information:
Global Edoxaban API Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Edoxaban API Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Edoxaban API companies in 2021 (%)
The global Edoxaban API market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Min Purity Less Than 98% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Edoxaban API include Tecoland, FCDA, UQUIFA, Glenmark Life Sciences, AlchemyPharm, Athos Chemicals, Jigs chemical, Shanghaizehan biopharma technology and Inner Mongolia Jingdong Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Edoxaban API manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Edoxaban API Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Edoxaban API Market Segment Percentages, by Type, 2021 (%)
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Global Edoxaban API Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Edoxaban API Market Segment Percentages, by Application, 2021 (%)
Research
Pharmaceutical
Global Edoxaban API Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Edoxaban API Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Edoxaban API revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Edoxaban API revenues share in global market, 2021 (%)
Key companies Edoxaban API sales in global market, 2017-2022 (Estimated), (MT)
Key companies Edoxaban API sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Tecoland
FCDA
UQUIFA
Glenmark Life Sciences
AlchemyPharm
Athos Chemicals
Jigs chemical
Shanghaizehan biopharma technology
Inner Mongolia Jingdong Pharmaceutical
Shengda Pharmaceutical
Tianyu Pharm

Frequently Asked Questions
Edoxaban API Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Edoxaban API Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Edoxaban API Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports